Valganciclovir and Risk for Neutropenia: When the Friend Becomes the Foe

Affiliations

¹ Department of Pharmacy, Transplant and Regenerative Medicine Centre, Hospital for Sick Children, Toronto, Ontario, Canada.
² Division of Nephrology, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
³ Division of Infectious Diseases, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

Editorial

Nadya Nalli et al. Pediatr Transplant. 2024 Aug.

. 2024 Aug;28(5):e14817.

doi: 10.1111/petr.14817.

¹ Department of Pharmacy, Transplant and Regenerative Medicine Centre, Hospital for Sick Children, Toronto, Ontario, Canada.
² Division of Nephrology, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
³ Division of Infectious Diseases, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

No abstract available

Keywords: neutropenia; solid organ transplant; valganciclovir.

References

1. C. N. Kotton, D. Kumar, A. M. Caliendo, et al., “The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid‐Organ Transplantation,” Transplantation 102 (2018): 900–931.
1. K. G. Valencia Deray, K. E. Hosek, D. Chilukuri, et al., “Epidemiology and Long‐Term Outcomes of Cytomegalovirus DNAemia and Disease in Pediatric Solid Organ Transplant Recipients,” American Journal of Transplantation 22, no. 1 (2022): 187–198.
1. Valcyte Product Monograph, Hoffman‐Lar Roche Ltd. Initial authorization May 2002; revised September 2021.
1. S. Belga, C. Hernandez, D. Kabbani, and C. Cervera, “Incidence of Valganciclovir‐Related Leukopenia and Neutropenia in Solid Organ Transplant Recipients at High Risk of Cytomegalovirus Disease,” Transplant Infectious Disease 5 (January 2024): e14227, https://doi.org/10.1111/tid.14227.
1. W. Zhao, V. Baudouin, D. Zhang, G. Deschênes, C. L. Guellec, and E. Jacqz‐Aigrain, “Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Pediatric Renal Transplant Patients,” Clinical Pharmacokinetics 48, no. 5 (2009): 321–328.